Literature DB >> 11264438

Impairment of the Golgi GDP-L-fucose transport and unresponsiveness to fucose replacement therapy in LAD II patients.

L Sturla1, L Puglielli, M Tonetti, P Berninsone, C B Hirschberg, A De Flora, A Etzioni.   

Abstract

Leukocyte adhesion deficiency type II is an autosomal recessive syndrome characterized by generalized reduction of L-fucose in glycoconjugates; the specific molecular defect is still undefined. The most important clinical symptoms include severe growth and mental retardation and severe immunodeficiency. Patients from two ethnic groups have been reported, i.e. Arab and Turkish. We have observed that GDP-L-fucose transport into Golgi vesicles was specifically impaired in an Arab patient, with a significant reduction of the V:(max) but no significant differences in the K:(m) from control and parents. GDP-L-fucose transport showed simple saturation kinetics in all samples. Transport of UDP-galactose, UDP-N:-acetylglucosamine, and CMP-sialic acid was comparable into vesicles from the Arab patient, parents, and control. These kinetic parameters probably account for the failure to obtain any clinical and biochemical response to fucose therapy in Arab patients. This contrasts both with the distinctive kinetic properties of GDP-L-fucose transport and with the success of fucose therapy, which have been recently reported in one patient of Turkish origin. Accordingly, the biochemical properties of GDP-L-fucose transport into the Golgi are consistent with different variants of leukocyte adhesion deficiency type II that are probably the result of different molecular defects.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11264438     DOI: 10.1203/00006450-200104000-00016

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  19 in total

Review 1.  Golgi nucleotide sugar transport and leukocyte adhesion deficiency II.

Authors:  C B Hirschberg
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.

Authors:  Fabio Candotti; Luigi Notarangelo; Roberta Visconti; John O'Shea
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Loss of α1,6-Fucosyltransferase Decreases Hippocampal Long Term Potentiation: IMPLICATIONS FOR CORE FUCOSYLATION IN THE REGULATION OF AMPA RECEPTOR HETEROMERIZATION AND CELLULAR SIGNALING.

Authors:  Wei Gu; Tomohiko Fukuda; Tomoya Isaji; Qinglei Hang; Ho-hsun Lee; Seiichiro Sakai; Jyoji Morise; Junya Mitoma; Hideyoshi Higashi; Naoyuki Taniguchi; Hiromu Yawo; Shogo Oka; Jianguo Gu
Journal:  J Biol Chem       Date:  2015-05-15       Impact factor: 5.157

Review 4.  The role of nucleotide sugar transporters in development of eukaryotes.

Authors:  Li Liu; Yu-Xin Xu; Carlos B Hirschberg
Journal:  Semin Cell Dev Biol       Date:  2010-02-06       Impact factor: 7.727

5.  The Drosophila neurally altered carbohydrate mutant has a defective Golgi GDP-fucose transporter.

Authors:  Christoph Geisler; Varshika Kotu; Mary Sharrow; Dubravko Rendić; Gerald Pöltl; Michael Tiemeyer; Iain B H Wilson; Donald L Jarvis
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

6.  Komrower Lecture. Congenital disorders of glycosylation (CDG): it's all in it!

Authors:  J Jaeken
Journal:  J Inherit Metab Dis       Date:  2003       Impact factor: 4.982

Review 7.  Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature.

Authors:  Yael Gazit; Adi Mory; Amos Etzioni; Moshe Frydman; Oded Scheuerman; Ruth Gershoni-Baruch; Ben-Zion Garty
Journal:  J Clin Immunol       Date:  2010-01-23       Impact factor: 8.317

Review 8.  Molecular physiology and pathology of the nucleotide sugar transporter family (SLC35).

Authors:  Nobuhiro Ishida; Masao Kawakita
Journal:  Pflugers Arch       Date:  2003-05-21       Impact factor: 3.657

Review 9.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

Review 10.  Therapies and therapeutic approaches in Congenital Disorders of Glycosylation.

Authors:  Christian Thiel; Christian Körner
Journal:  Glycoconj J       Date:  2012-09-16       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.